

# EXPERIENCE THE LATEST IN SINGLE-CELL TECHNOLOGY AT ACTC

## POSTER PRESENTATION:

### *“Combined Single-Cell Analysis of Solid Tumors and CTCs for Comprehensive Patient Management”*

**Non-small cell lung cancer (NSCLC) has a poor prognosis as most patients are at an advanced stage when diagnosed.** However, targeted therapy and immunotherapy in recent years have significantly improved NSCLC patient outcome. See how we used single-cell immunophenotype and cancer biomarker profiling of primary tumor cells to investigate signatures that may predict the presence of circulating tumor cells (CTCs).

## ADDITIONAL INFORMATION:

**Featured Speaker:** Bruce Patterson, MD - CEO & Founder, IncellDx

### What you will learn:

- Profiling multiple immune and cancer markers on cancer samples with multi-parametric flow cytometry allows protein expression information at the single cell level.
- Clustering analysis of the proteomic data revealed a signature driven by checkpoint marker expression on CD103+CD4+ T cells that could potentially be predictive of CTCs.
- Learn more about our new comprehensive suite of products to help optimize yield and analysis of CTCs.



*Bruce Patterson, IncellDx*

**Date:** Wednesday, October 2 | **Time:** 15:20 - 15:30



**STOP BY OUR BOOTH #12 TO LEARN MORE  
AND ENTER TO WIN AN APPLE WATCH!\***

*\*Winner will be selected on the last day of the conference and will need to be present to come by the booth and pick it up. Good luck and thanks for coming by!*